Department of Breast Medical Oncology and Phase I Program, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Clin Breast Cancer. 2010 Sep;10 Suppl 2:S30-40. doi: 10.3816/CBC.2010.s.010.
Novel therapies are emerging for treatment of patients with localized or advanced breast cancer. Targeted therapies such as trastuzumab, lapatinib, and bevacizumab have demonstrated significant clinical benefit in the metastatic setting, and trastuzumab has also improved patient outcome as adjuvant therapy in HER2+ breast cancer. Novel chemotherapies are also being developed to improve drug delivery, enhance efficacy, or decrease drug toxicity. These novel cytotoxic agents are being combined with established targeted therapies and are showing early promise for the treatment of patients with advanced breast cancer. Finally, new targeted therapies have shown clinical benefit, either as single agents or in combination with established targeted therapy or chemotherapy.
新型疗法不断涌现，用于治疗局部晚期或转移性乳腺癌患者。曲妥珠单抗、拉帕替尼和贝伐珠单抗等靶向治疗药物在转移性乳腺癌中已显示出显著的临床获益，曲妥珠单抗也已作为 HER2+乳腺癌的辅助治疗改善了患者的预后。新型化疗药物也在不断开发中，以改善药物递送、提高疗效或降低药物毒性。这些新型细胞毒性药物与已确立的靶向治疗联合使用，为治疗晚期乳腺癌患者带来了早期希望。最后，新型靶向治疗药物无论是单药治疗还是与已确立的靶向治疗或化疗联合应用，均显示出了临床获益。
Zotero 插件